Literature DB >> 21365781

Bronchoscopy in cystic fibrosis infants diagnosed by newborn screening.

Patrick Stafler1, Jane C Davies, Ian M Balfour-Lynn, Mark Rosenthal, Andrew Bush.   

Abstract

BACKGROUND: There is evidence of early functional and structural changes in babies with cystic fibrosis (CF) diagnosed on newborn screening (NBS). The aim of the present study was to determine the yield of bronchoalveolar lavage (BAL) microbiology and cytology, and 24 hr pH monitoring in a group of CF infants diagnosed on NBS.
METHODS: Infants referred to a tertiary pediatric respiratory center between July 2007 and November 2009 underwent surveillance fiber-optic bronchoscopy (FOB), BAL, and insertion of a 24 hr dual pH probe under a single general anesthetic.
RESULTS: We studied 33 infants, median age of 100 days (47-215 days) at the time of FOB. In 9 of 33 (27%) bacterial organisms were identified. Seven of the nine patients (78%) were asymptomatic and only one had had a positive cough swab prior to FOB. Neutrophilia was identified in 18/27 (67%) cases with a median of 11% (6-73%). 13/31 (42%) had an abnormal pH study with a pH index >12%.
CONCLUSIONS: The high yield of microbiology, cytology, and pH probe investigations in NBS infants justifies invasive surveillance. Longitudinal studies to determine if early aggressive treatment results in improved outcome are awaited.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21365781     DOI: 10.1002/ppul.21434

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  9 in total

1.  Regional differences in the evolution of lung disease in children with cystic fibrosis.

Authors:  Zhanhai Li; Don B Sanders; Michael J Rock; Michael R Kosorok; Jannette Collins; Christopher G Green; Alan S Brody; Philip M Farrell
Journal:  Pediatr Pulmonol       Date:  2011-12-07

Review 2.  Cystic fibrosis.

Authors:  Felix Ratjen; Scott C Bell; Steven M Rowe; Christopher H Goss; Alexandra L Quittner; Andrew Bush
Journal:  Nat Rev Dis Primers       Date:  2015-05-14       Impact factor: 52.329

3.  Impaired defenses of neonatal mouse alveolar macrophage with cftr deletion are modulated by glutathione and TGFβ1.

Authors:  Theresa W Gauthier; Jocelyn R Grunwell; Xiao-Du Ping; Frank L Harris; Lou Ann S Brown
Journal:  Physiol Rep       Date:  2017-03

4.  Heparin-binding protein in sputum as a marker of pulmonary inflammation, lung function, and bacterial load in children with cystic fibrosis.

Authors:  Gisela Hovold; Victoria Palmcrantz; Fredrik Kahn; Arne Egesten; Lisa I Påhlman
Journal:  BMC Pulm Med       Date:  2018-06-20       Impact factor: 3.317

5.  Longitudinal development of the airway microbiota in infants with cystic fibrosis.

Authors:  Bushra Ahmed; Michael J Cox; Leah Cuthbertson; Phillip James; William O C Cookson; Jane C Davies; Miriam F Moffatt; Andrew Bush
Journal:  Sci Rep       Date:  2019-03-26       Impact factor: 4.379

Review 6.  Exploring the Cystic Fibrosis Lung Microbiome: Making the Most of a Sticky Situation.

Authors:  Christina S Thornton; Nicole Acosta; Michael G Surette; Michael D Parkins
Journal:  J Pediatric Infect Dis Soc       Date:  2022-09-07       Impact factor: 5.235

Review 7.  Bronchoscopy-guided antimicrobial therapy for cystic fibrosis.

Authors:  Kamini Jain; Claire Wainwright; Alan R Smyth
Journal:  Cochrane Database Syst Rev       Date:  2018-09-17

8.  Airway Microbiota in Bronchoalveolar Lavage Fluid from Clinically Well Infants with Cystic Fibrosis.

Authors:  Theresa A Laguna; Brandie D Wagner; Cynthia B Williams; Mark J Stevens; Charles E Robertson; Cole W Welchlin; Catherine E Moen; Edith T Zemanick; Jonathan K Harris
Journal:  PLoS One       Date:  2016-12-08       Impact factor: 3.240

9.  Comparison of the upper and lower airway microbiota in children with chronic lung diseases.

Authors:  Bushra Ahmed; Michael J Cox; Leah Cuthbertson; Phillip L James; William O C Cookson; Jane C Davies; Miriam F Moffatt; Andrew Bush
Journal:  PLoS One       Date:  2018-08-02       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.